Evidence map›Paper›PMID 33571795›Full record

ArticleJournal of affective disorders2021

Comments to Drs. Bahji, Vazquez, and Zarate.

Wayne C Drevets, Vanina Popova, Ella J Daly, Stephane Borentain, Rosanne Lane, M Soledad Cepeda, Maju Mathews, Husseini K Manji, Carla M Canuso

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of affective disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Wayne C DrevetsNeuroscience Clinical Development, Janssen Research & Development, LLC, San Diego, CA, USA. Electronic address: wdrevets@its.jnj.com.
Vanina PopovaNeuroscience Clinical Development, Janssen Research & Development, Beerse, Belgium.
Ella J DalyNeuroscience Medical Affairs, Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
Stephane BorentainGlobal Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA.
Rosanne LaneClinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA.
M Soledad CepedaEpidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA.
Maju MathewsGlobal Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA.
Husseini K ManjiNeuroscience Clinical Development, Janssen Research & Development, LLC, Titusville, NJ, USA.
Carla M CanusoNeuroscience Clinical Development, Janssen Research & Development, LLC, Titusville, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the absence of head-to-head studies directly comparing the efficacy of intranasal esketamine to that of intravenous ketamine, valid conclusions regarding comparative efficacy cannot be made based on the existing data from trials using markedly differing study designs and patient populations.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineMajor Depressive DisorderAntidepressive AgentsDepressionHumansAntidepressive AgentsEsketamineKetamineDepressionEsketamineKetamineMajor depressive disorder

Identifiers

PMID33571795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.